SignificanceTranscriptional coactivators and their partner transcription factors have been labeled as intrinsically disordered, fuzzy, and undruggable. We propose that the identification of conserved mechanisms of engagement between coactivators and their cognate activators should provide general principles for small-molecule modulator discovery. Here, we show that the structurally divergent coactivator Med25 forms short-lived and dynamic complexes with three different transcriptional activators and that conformational shifts are mediated by a flexible substructure of two dynamical helices and flanking loops. Analogous substructures are found across coactivators. Further, targeting one of the flexible structures with a small molecule modulates Med25–activator complexes. Thus, the two conclusions of the work are actionable for the discovery of small-molecule modulators of this functionally important protein class.
A key functional event in eukaryotic gene activation is the formation of dynamic protein–protein interaction networks between transcriptional activators and transcriptional coactivators. Seemingly incongruent with the tight regulation of transcription, many biochemical and biophysical studies suggest that activators use nonspecific hydrophobic and/or electrostatic interactions to bind to coactivators, with few if any specific contacts. Here a mechanistic dissection of a set of representative dynamic activator•coactivator complexes, comprised of the ETV/PEA3 family of activators and the coactivator Med25, reveals a different molecular recognition model. The data demonstrate that small sequence variations within an activator family significantly redistribute the conformational ensemble of the complex while not affecting overall affinity, and distal residues within the activator—not often considered as contributing to binding—play a key role in mediating conformational redistribution. The ETV/PEA3•Med25 ensembles are directed by specific contacts between the disordered activator and the Med25 interface, which is facilitated by structural shifts of the coactivator binding surface. Taken together, these data highlight the critical role coactivator plasticity plays in recognition of disordered activators and indicate that molecular recognition models of disordered proteins must consider the ability of the binding partners to mediate specificity.
The protein–protein interaction
between the KIX motif of
the transcriptional coactivator CBP/p300 and the transcriptional activator
Myb is a high-value target due to its established role in certain
acute myeloid leukemias (AML) and potential contributions to other
cancers. However, the CBP/p300 KIX domain has multiple binding sites,
several structural homologues, many binding partners, and substantial
conformational plasticity, making it challenging to specifically target
using small-molecule inhibitors. Here, we report a picomolar dual-site
inhibitor (MybLL-tide) of the Myb–CBP/p300 KIX interaction.
MybLL-tide has higher affinity for CBP/p300 KIX than any previously
reported compounds while also possessing 5600-fold selectivity for
the CBP/p300 KIX domain over other coactivator domains. MybLL-tide
blocks the association of CBP and p300 with Myb in the context of
the proteome, leading to inhibition of key Myb·KIX-dependent
genes in AML cells. These results show that MybLL-tide is an effective,
modifiable tool to selectively target the KIX domain and assess transcriptional
effects in AML cells and potentially other cancers featuring aberrant
Myb behavior. Additionally, the dual-site design has applicability
to the other challenging coactivators that bear multiple binding surfaces.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.